News Releases Archive — Page 1 of 40
Recent and archived press releases with clinical and research news
-
September 7, 2026
Researchers identify new therapeutic target for salt-sensitive hypertension
The Vanderbilt Health team discovered that a signaling pathway called AP-1 complex links dietary sodium to immune-driven salt-sensitivity of blood pressure, which increases the risk of cardiovascular disease and death. -
September 7, 2026
Gibson Gives strikes the right chord with Vanderbilt Health for healing
Donated guitars help artists recover and return to making music. -
September 2, 2026
Peter Embí named Director of the National Library of Medicine at NIH
Vanderbilt Health informatics leader will head the world’s largest biomedical library and the nation’s leading funder of biomedical informatics and data science research. -
September 1, 2026
The Case of the Missing Statue: Red Paper Dolls vanish for a secret makeover!
The nearly 9-foot-tall, 1,500-pound, aluminum sculpture has served as the logo for the hospital since 1971, and now those iconic paper dolls are getting a dose of rehab therapy. Watch a timelapse video of the removal! -
August 31, 2026
Firefly expands to Vanderbilt Wilson County Hospital and other regional clinics
Vanderbilt Health’s clinical care and support program for pregnant and postpartum women with substance use disorder has served 27 pregnant patients at VWCH, with the goal of serving 50-100 patients annually. -
August 26, 2026
Duchenne muscular dystrophy patients are focus of GLP-1 therapy for obesity study
The study will begin enrolling eligible patients in September. Thirty participants, ages 12 and older, will be randomized to receive either a placebo or the GLP-1 receptor agonist semaglutide. -
August 20, 2026
Her muscles are slowly turning to bone. She was the only American in a trial that might stop it.
As part of the clinical trial, Jordyn Bugarin regularly traveled to Vanderbilt Health, navigating a complex study while living with a disease that can flare unpredictably and permanently limit movement. The experimental drug received federal approval Aug. 19.